The WNT5a ligand can be provided by mesenchymal stromal cells (MSCs) in the bone marrow or by ROR (NLCs) and thereby mobilize CLL cells, as well as contributing to the resistance of CLL to venetoclax [33,38]. Here, WNT5A is linked to B-cell chronic lymphocytic leukemia.